{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:45:58Z","timestamp":1790401558122,"version":"4.1.0"},"reference-count":128,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2021,2,27]],"date-time":"2021-02-27T00:00:00Z","timestamp":1614384000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Epilepsia"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Developmental and epileptic encephalopathies (DEEs) are among the most challenging of all epilepsies to manage, given the exceedingly frequent and often severe seizure types, pharmacoresistance to conventional antiseizure medications, and numerous comorbidities. During the past decade, efforts have focused on development of new treatment options for DEEs, with several recently approved in the United States or Europe, including cannabidiol as an orphan drug in Dravet and Lennox\u2013Gastaut syndromes and everolimus as a possible antiepileptogenic and precision drug for tuberous sclerosis complex, with its impact on the mammalian target of rapamycin pathway. Furthermore, fenfluramine, an old drug, was repurposed as a novel therapy in the treatment of Dravet syndrome. The evolution of new insights into pathophysiological processes of various DEEs provides possibilities to investigate novel and repurposed drugs and to place them into the context of their role in future management of these patients. The purpose of this review is to provide an overview of these new medical treatment options for the DEEs and to discuss the clinical implications of these results for improved treatment.<\/jats:p>","DOI":"10.1111\/epi.16849","type":"journal-article","created":{"date-parts":[[2021,2,27]],"date-time":"2021-02-27T06:30:06Z","timestamp":1614407406000},"page":"857-873","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["The role of new medical treatments for the management of developmental and epileptic encephalopathies: Novel concepts and results"],"prefix":"10.1111","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0877-8912","authenticated-orcid":false,"given":"Cecilie","family":"Johannessen Landmark","sequence":"first","affiliation":[{"name":"Program for Pharmacy Department of Life Sciences and Health Faculty of Health Sciences Oslo Metropolitan University Oslo Norway"},{"name":"National Center for Epilepsy Oslo University Hospital Oslo Norway"},{"name":"Section for Clinical Pharmacology Department of Pharmacology Oslo University Hospital Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1506-0252","authenticated-orcid":false,"given":"Heidrun","family":"Potschka","sequence":"additional","affiliation":[{"name":"Institute of Pharmacology, Toxicology, and Pharmacy Ludwig Maximilian University of Munich Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3874-9749","authenticated-orcid":false,"given":"St\u00e9phane","family":"Auvin","sequence":"additional","affiliation":[{"name":"Pediatric Neurology Department Robert Debr\u00e9 Hospital Public Hospital Network of Paris Paris France"},{"name":"Mixed Unit of Research NeuroDiderot U1141 University of Paris Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7328-1796","authenticated-orcid":false,"given":"Jo M.","family":"Wilmshurst","sequence":"additional","affiliation":[{"name":"Paediatric Neurology Department Red Cross War Memorial Children\u2019s Hospital Neuroscience Institute University of Cape Town Cape Town South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7087-6655","authenticated-orcid":false,"given":"Svein I.","family":"Johannessen","sequence":"additional","affiliation":[{"name":"National Center for Epilepsy Oslo University Hospital Oslo Norway"},{"name":"Section for Clinical Pharmacology Department of Pharmacology Oslo University Hospital Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6659-2614","authenticated-orcid":false,"given":"Doroth\u00e9e","family":"Kasteleijn\u2010Nolst Trenit\u00e9","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery and Epilepsy University Medical Center Utrecht Utrecht the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3015-8282","authenticated-orcid":false,"given":"Elaine C.","family":"Wirrell","sequence":"additional","affiliation":[{"name":"Divisions of Child and Adolescent Neurology and Epilepsy Mayo Clinic Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,2,27]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.13709"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2010.02522.x"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2017.01.011"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2012-3998"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2016.10.006"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1017\/cjn.2016.249"},{"issue":"18","key":"e_1_2_7_8_1","first-page":"e3","article-title":"Optimizing the diagnosis and management of Dravet syndrome: recommendations from a North American consensus panel","volume":"68","author":"Wirrell EC","year":"2017","journal-title":"Pediatr Neurol"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-019-00666-8"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/epi4.12413"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000781"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2020.1724956"},{"key":"e_1_2_7_13_1","article-title":"Progress report on new antiepileptic drugs: a summary of the Fifteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XV). I. Drugs in preclinical and early clinical development","author":"Bialer M","year":"2020","journal-title":"Epilepsia"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2016.11.033"},{"issue":"1","key":"e_1_2_7_15_1","first-page":"S16","article-title":"Pharmacology and drug interactions of cannabinoids","volume":"22","author":"Johannessen Landmark C","year":"2020","journal-title":"Epileptic Disord"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1684\/epd.2020.1141"},{"key":"e_1_2_7_17_1","article-title":"Progress report on new antiepileptic drugs: a summary of the Fifteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XV). II. Drugs in more advanced clinical development","author":"Bialer M","year":"2020","journal-title":"Epilepsia"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2019.107417"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.459"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31419-2"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51229"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-019-00739-y"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXG.0000000000000096"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.39"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001926"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2020.107187"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/mgg3.1250"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000006199"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2019.106222"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611618"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30136-3"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.14670"},{"key":"e_1_2_7_33_1","unstructured":"ThieleE BebinEM BhathalH JansenF Kotulska\u2010J\u00f3\u017awiakK LawsonJA et al.Cannabidiol (CBD) treatment in patients with seizures associated with tuberous sclerosis complex: a randomized double\u2010blind placebo\u2010controlled phase 3 trial (GPWCARE6). American Epilepsy Society Annual Meeting 2019. Abstract 1.293.https:\/\/www.aesnet.org\/meetings_events\/annual_meeting_abstracts\/view\/2421288. Accessed 28 Jan 2020."},{"key":"e_1_2_7_34_1","unstructured":"Phase 2 ELEKTRA study of soticlestat (TAK\u2010935\/OV935) meets primary endpoint reducing seizure frequency in children with Dravet syndrome or Lennox\u2010Gastaut syndrome.https:\/\/www.takeda.com\/newsroom\/newsreleases\/2020\/phase\u20102\u2010elektra\u2010study\u2010of\u2010soticlestat\u2010tak\u2010935ov935\u2010meets\u2010primary\u2010endpoint\u2010reducing\u2010seizure\u2010frequency\u2010in\u2010children\u2010with\u2010dravet\u2010syndrome\u2010or\u2010lennox\u2010gastaut\u2010syndrome\/. Accessed 1 Dec 2020."},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.50998"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2017.05.017"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.14540"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.4113"},{"key":"e_1_2_7_39_1","unstructured":"KnuppKG SchefferIE CeulemansB SullivanJ NickelsKC MillerI et al.Efficacy and safety of fintepla (fenfluramine) for the treatment of seizures associated with Lennox\u2010Gastaut syndrome: a randomized double\u2010blind placebo\u2010controlled clinical trial. American Epilepsy Society Annual Meeting 2020. Abstract 852.https:\/\/www.eventscribe.net\/2020\/AES2020\/. Accessed 8 Dec 2020."},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsb1503104"},{"issue":"3","key":"e_1_2_7_41_1","first-page":"669","article-title":"Clemizole and modulators of serotonin singnalling suppress seizures in Dravet syndrome","volume":"140","author":"Griffin A","year":"2017","journal-title":"Brain"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000000514"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-4642(18)30099-3"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpn.2018.05.006"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2019.1635457"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S145630"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2004.03.007"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.14085"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1586\/ern.09.136"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1177\/0883073814544703"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.14529"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-019-1077-6"},{"key":"e_1_2_7_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpn.2018.06.007"},{"key":"e_1_2_7_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2017.02.007"},{"key":"e_1_2_7_55_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12502"},{"key":"e_1_2_7_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/nan.12463"},{"key":"e_1_2_7_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2018.08.002"},{"key":"e_1_2_7_58_1","doi-asserted-by":"publisher","DOI":"10.1177\/0883073808324535"},{"key":"e_1_2_7_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2018.09.020"},{"key":"e_1_2_7_60_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003077"},{"key":"e_1_2_7_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2020.03.018"},{"key":"e_1_2_7_62_1","doi-asserted-by":"publisher","DOI":"10.1097\/SCS.0000000000007034"},{"key":"e_1_2_7_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2019.10.007"},{"key":"e_1_2_7_64_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10545-009-1045-8"},{"key":"e_1_2_7_65_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1712649"},{"key":"e_1_2_7_66_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaz6100"},{"key":"e_1_2_7_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2016.05.011"},{"key":"e_1_2_7_68_1","doi-asserted-by":"publisher","DOI":"10.1177\/1535759718822846"},{"key":"e_1_2_7_69_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25959"},{"key":"e_1_2_7_70_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2015.116"},{"key":"e_1_2_7_71_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2014-309388"},{"key":"e_1_2_7_72_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25439"},{"key":"e_1_2_7_73_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24806"},{"key":"e_1_2_7_74_1","doi-asserted-by":"publisher","DOI":"10.1002\/epi4.12317"},{"key":"e_1_2_7_75_1","unstructured":"MartinJA Berrios\u2010SiervoG EschbachK.Long\u2010term outcomes in a patient with febrile infection\u2010related epilepsy syndrome (FIRES) treated with anakinra. 71st Annual Meeting of the American Epilepsy Society; Washington DC; December 1\u20135 2017. Abstract 2.421.https:\/\/www.aesnet.org\/meetings_events\/annual_meeting_abstracts\/view\/349145. Accessed 18 Jan 2018."},{"key":"e_1_2_7_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpn.2019.08.001"},{"key":"e_1_2_7_77_1","first-page":"135","article-title":"Febrile infecton\u2010related epilepsy syndrome treated successfully with anakinra in a 21\u2010year\u2010old woman","volume":"118","author":"Westbrook C","year":"2019","journal-title":"WMJ"},{"key":"e_1_2_7_78_1","unstructured":"RathS.Multi\u2010drug regimen including anakinra cannabidiol and ketogenic diet in the management of refractory seizures in a patient with FIRES. 72nd Annual Meeting of the American Epilepsy Society; New Orleans LA; November 30\u2013December 4 2018. Abstract 3.447.https:\/\/www.aesnet.org\/meetings_events\/annual_meeting_abstracts\/view\/506245. Accessed 19 Feb 2020."},{"issue":"15","key":"e_1_2_7_79_1","first-page":"346","article-title":"Anakinra (IL\u20101 blockade) use in children with suspected FIRES: a single institution experience","volume":"90","author":"Shukla N","year":"2018","journal-title":"Neurology"},{"key":"e_1_2_7_80_1","first-page":"956","article-title":"Febrile infection\u2010related epilepsy syndrome (FIRES): pathogenesis, treatment, and outcome: a multicenter study on 77 children","volume":"52","author":"Kramer U","year":"2011","journal-title":"Epilepsia"},{"key":"e_1_2_7_81_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2017.3949"},{"key":"e_1_2_7_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32500-0"},{"key":"e_1_2_7_83_1","doi-asserted-by":"publisher","DOI":"10.1111\/dmcn.13591"},{"key":"e_1_2_7_84_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25956"},{"key":"e_1_2_7_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03157-3"},{"key":"e_1_2_7_86_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2011.03008.x"},{"key":"e_1_2_7_87_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.12-11-04151.1992"},{"key":"e_1_2_7_88_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-017-0432-1"},{"key":"e_1_2_7_89_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa1299"},{"key":"e_1_2_7_90_1","doi-asserted-by":"publisher","DOI":"10.1002\/glia.23316"},{"key":"e_1_2_7_91_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12401"},{"key":"e_1_2_7_92_1","doi-asserted-by":"publisher","DOI":"10.1002\/jnr.23688"},{"key":"e_1_2_7_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2014.10.014"},{"key":"e_1_2_7_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2015.03.012"},{"key":"e_1_2_7_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2014.02.008"},{"key":"e_1_2_7_96_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12303"},{"key":"e_1_2_7_97_1","doi-asserted-by":"publisher","DOI":"10.1111\/ane.12611"},{"key":"e_1_2_7_98_1","doi-asserted-by":"publisher","DOI":"10.1111\/ane.12403"},{"key":"e_1_2_7_99_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2016.12.020"},{"key":"e_1_2_7_100_1","doi-asserted-by":"publisher","DOI":"10.1111\/ane.12888"},{"key":"e_1_2_7_101_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1999.tb02048.x"},{"key":"e_1_2_7_102_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2014.03.009"},{"key":"e_1_2_7_103_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.14555"},{"key":"e_1_2_7_104_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2016.11.006"},{"key":"e_1_2_7_105_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2016.11.012"},{"key":"e_1_2_7_106_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-015-0377-3"},{"key":"e_1_2_7_107_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-020-00931-w"},{"key":"e_1_2_7_108_1","doi-asserted-by":"publisher","DOI":"10.1684\/epd.2020.1135"},{"key":"e_1_2_7_109_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-018-0578-5"},{"key":"e_1_2_7_110_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000005254"},{"key":"e_1_2_7_111_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2018.05.013"},{"key":"e_1_2_7_112_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.13060"},{"key":"e_1_2_7_113_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.665"},{"key":"e_1_2_7_114_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.16071"},{"key":"e_1_2_7_115_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-74036-6"},{"key":"e_1_2_7_116_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199608293350901"},{"key":"e_1_2_7_117_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528-1157.2002.casa432.x"},{"key":"e_1_2_7_118_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2012.03495.x"},{"key":"e_1_2_7_119_1","doi-asserted-by":"publisher","DOI":"10.1016\/0091-3057(88)90089-5"},{"key":"e_1_2_7_120_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-3057(01)00669-4"},{"key":"e_1_2_7_121_1","first-page":"191","article-title":"Pharmacological analysis of the anti\u2010epileptic mechanisms of fenfluramine in scn1a mutant zebrafish","volume":"8","author":"Sourbon J","year":"2017","journal-title":"Front Pharmacol"},{"issue":"1","key":"e_1_2_7_122_1","first-page":"75","article-title":"Possible role of valvular serotonin 5\u2010HT(2B) receptors in the cardiopathy associated with fenfluramine","volume":"57","author":"Fitzgerald LW","year":"2000","journal-title":"Mol Pharmacol"},{"key":"e_1_2_7_123_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00223"},{"key":"e_1_2_7_124_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-50174-1_10"},{"key":"e_1_2_7_125_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.16722"},{"issue":"15","key":"e_1_2_7_126_1","article-title":"Safety and efficacy of add\u2010on ZX008 (fenfluramine HCL oral solution) in sunflower syndrome: an open\u2010label pilot study of 5 patients","volume":"94","author":"Thiele EA","year":"2020","journal-title":"Neurology"},{"key":"e_1_2_7_127_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01223-9"},{"key":"e_1_2_7_128_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2015.04.016"},{"key":"e_1_2_7_129_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.14551"}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/epi.16849","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/epi.16849","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/epi.16849","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T13:54:52Z","timestamp":1692626092000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/epi.16849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,27]]},"references-count":128,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["10.1111\/epi.16849"],"URL":"https:\/\/doi.org\/10.1111\/epi.16849","archive":["Portico"],"relation":{},"ISSN":["0013-9580","1528-1167"],"issn-type":[{"value":"0013-9580","type":"print"},{"value":"1528-1167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,27]]},"assertion":[{"value":"2020-12-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}